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The anticancer effects of ceramide have been reported in many types of cancers but less in lung cancer. In this
study, we used C2-ceramide to further investigate its possible anticancer effects and mechanisms on non-small cell
lung cancer (NSCLC) H1299 cells. The result of cell proliferation in terms of trypan blue assay showed high dose of
C2-ceramide inhibited cell survival after 24 h treatment. The flow cytometry-based assays indicated the effect of
apoptosis, chromatin condensation, and G1 arrest in terms of Annexin V/propidium iodide (PI), DAPI, and PI stainings,
respectively. Moreover, the decreased protein level of p-Akt, p-NFκB, survivin and cyclin A2 were detected by Western
blot assay. Taken together, these results indicated the antiproliferative effect of C2-ceramide is majorly responsible for
cell apoptosis in lung cancer H1299 cells.
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Approximately 80% of lung cancer belongs to non-
small-cell lung cancer (NSCLC) and the other is SCLC
histologically [1]. Although smoking is one of the main
risk factors for lung cancer [2], about 10% patients are
non-smokers [3]. NSCLC is generally detected and diag-
nosed at late stage and its prognosis is poor [4]. There-
fore, the anticancer drugs for NSCLC treatment remain
a challenge.
Akt, a serine/threonine kinase, regulates cell growth,
cell cycle progression, survival and anti-apoptosis. Dys-
regulation of Akt was reported to be observed in various
cancers including breast cancer [5] and lung cancer cells
[6]. Furthermore, the constitutive activation of Akt has
been shown to cause chemoresistant of cancer cells.
Similarly, NFκB, an inflammatory-associated transcrip-
tion factor, is also found to be constitutively activated* Correspondence: cchiu@kmu.edu.tw
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reproduction in any medium, provided the oror aberrantly expressed in lung cancer [7,8]. Therefore,
targeting of Akt and NFκB signaling seems to be a
promising strategy for lung cancer therapy [9-12].
Ceramides are important components composed of
lipid molecules and can form into sphingolipids when
added functional groups on their hydroxyl group such as
phosphate choline or monosaccharide. When cells are
triggered by certain stimuli, an enzyme called sphingo-
myelinase [13] would hydrolyze sphingolipids and cause
the release of ceramides into cytoplasm, which can
undergo many biological processes, such as differenti-
ation, proliferation, growth arrest and apoptosis [14].
Ceramide was reported to act as an important medi-
ator in apoptosis pathways. Exogenous ceramides have
been demonstrated to induce anti-proliferation and
apoptosis in many cancers [15]. Furthermore, accumu-
lating evidence showed that ceramide inhibits prolifer-
ation of cancer cells via inhibiting Akt and NFκB signal
pathways [16,17].
The ceramide-mediated anticancer effects have been
reported in many types of cancers such as pancreatic
[18], breast [19], gastric [20], hematologic [21] cancer.
However, the final outcome of ceramide treatment may
depend on the context of cell types. Previous studies. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Effect of C2-Ceramide on proliferation of H1299 cells.
The cell proliferation assay showed the inhibition of cell growth at
high dose of treatment for 24 h.
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bryonic fibroblasts toward C2-ceramide induced cell
death [22]. On the contrary, the above study also
found that C2-ceramide induces cell death and acti-
vation of NFκB in lung cancer H1299 cells [22]. The
effects of C2-ceramide on apoptosis of H1299 cells
were investigated previously [22,23]. In the current
study, we examined the growth inhibitory property
to NSCLC H1299 cells by C2-ceramide as well as its
possible apoptosis mechanism, especially inhibiting
Akt and NFκB pathways.
Materials and methods
Cell cultures
The H1299 lung cancer cells were maintained in DMEM
medium (Invitrogen, Carlsbad, CA USA) containing 10%
fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml
streptomycin, 0.03% glutamine and 1 mM sodium pyru-
vate [24] and kept at 37°C in a humidified atmosphere
with 5% CO2.
Cell survival assay
Cell survival was determined by the trypan blue dye exclu-
sion assay as previously described [25,26]. In brief, Cells
were seeded at a density of 1 × 105 cells per well. After 24 h
of incubation, the cells were treated with C2-ceramide
(#A7191, Sigma) at concentrations of 0, 10, 20, and 50 μM
for 24 h, then 0.2% trypan blue were added to wells. Finally,
the viable cells we are calculated by the Countess® Auto-
mated Cell Counter (Invitrogen, Diego, CA, USA). The
assay was triplicated and the IC50 was calculated by the
slope and intercept accordingly to two concentrations
of C2-ceramide between the half-maximal proliferative
inhibition.
Apoptosis assay
Apoptosis was detected by annexin/PI staining (Pharmingen,
San Diego, CA, USA) as previously described [27]. Briefly,
cells were treated with C2-ceramide at concentrations of
0, 10, 20, and 50 μM for 24 h. After collection, cells were
treated with 10 μg/ml of annexin V-fluorescein isothiocyan-
ate and 5 μg/ml of PI for analysis with a FACSCalibur™ flow
cytometer (Becton-Dickinson).
Chromatin condensation assay
5 × 105 H1299 cells were seeded onto a 6-well plate.
After 24 h, cells were treated with indicated concentra-
tions (0 to 50 μM) of ceramide for 24 h. After wards,
cells were stained with 5 μg/ml of DAPI for 3 mins at
37°C. The level of chromatin condensation was deter-
mined by a flow cytometry (Becton-Dickinson). At least
10,000 stained cells were counted and calculated as per-
centage of chromatin condensation compared to those
of the control cells.Cell cycle distribution
Propidium iodide (PI, Sigma, St. Louis, MO, USA) stain-
ing for DNA content measurement was performed as
described previously [28]. Briefly, cells were treated with
0, 10, 20, and 50 μM of C2-ceramide for 24 h. After col-
lection, cells were washed twice with PBS before 70%
ethanol fixation. After centrifugation, the cells were in-
cubated with 10 μg/ml PI and 10 μg/ml RNase A in PBS
for 15 min at room temperature in the dark. Cell cycle
analyses were performed using a FACSCalibur flowcyt-
ometer (Becton-Dickinson, Mansfield, MA, USA).
Western blotting
Western blot assay was performed as described previously
[27]. Briefly, cells were collected for lysate preparation.
After centrifugation, and protein concentrations of lysates
were determined. Protein lysates for 40 μg were loaded and
electrophoresed by 10% SDS-polyacrylamide gel (PAGE)
and then transferred to membrane. The membranes were
blocked with 5% non-fat milk. Subsequently, it was reacted
with primary antibodies against t-Akt (#1081), p-NFκB
(Ser536, #2220) and Bax (#1063, Epitomics, CA, USA);
t-NFκB (sc-8008), β-catenin (sc-7963) and p-Akt (Ser473,
sc-7985, Santa Cruz Biotech, Santa Cruz, CA, USA); Cyc-
lin A2 (GeneTex Co., Cat No. GTX103042); survivin
(AnaSpec, San Jose, CA, USA) and β-actin (#sc-8432,
Santa Cruz Biotech), and their corresponding secondary
antibodies. The ECL™ (Amersham Piscataway, NJ, USA)
chemiluminescence detection kit was applied.
Statistical analysis
All data are presented as mean ± S.D. Comparison be-
tween experimental groups and vehicle controls was
assessed by one-way ANOVA test.
Figure 2 Treatment with C2-ceramide induced different accumulations of G1 population in lung cancer H1299 cells. Cells were treated
with 0, 10, 20, and 50 μM C2-ceramide for 24 h. (a) Representative cell cycle distribution in C2-ceramide-treated H1299 cells. (b) Cell phase
percentages obtained for (a) in triplicate experiments.
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Anti-proliferative effects of C2-Ceramide-Treated H1299
lung cancer cells
In the trypan blue assay (Figure 1), the proliferation rates
at various concentrations of C2-ceramide (0, 10, 20, and
50 μM) after 24 h were 100.0 ± 2.3, 90.1 ± 3.2, 69.2 ± 2.8,
5.0 ± 3 (n = 3). The proliferation rate of C2-ceramide-
treated H1299 lung cancer cells significantly decreased inFigure 3 Treatment with C2-ceramide induced different apoptotic pro
and 50 μM C2-ceramide for 24 h. (a) Representative apoptotic profiles obta
cells. (b) Quantification analysis results for late apoptosis population (%). On
Asterisks indicate statistically significant differences compared to control (Pa dose–response manner (P < 0.001). The 50% inhibitory
concentration (24 h, IC50) of C2-ceramide for H1299 cells
was 22.9 μM.
G1 arrest of C2-Ceramide-treated H1299 lung cancer cells
The role of cell cycle interference in the C2-ceramide-
induced apoptosis of H1299 lung cancer cells was exam-
ined by the flow cytometry-based PI assay (Figure 2).files in lung cancer H1299 cells. Cells were treated with 0, 10, 20,
ined by Annexin V/PI double staining in C2-ceramide-treated H1299
ly annexin V (+)/PI (+) regions were analyzed. Data, mean ± SD (n = 3).
< 0.001).
Figure 4 C2-ceramide increased chromatin condensation levels of H1299 lung cancer cells. (a) Flow cytometry-based DAPI profiles for
C2-ceramide-treated cells. Cells treated with different concentrations (0 to 50 μM) of C2-ceramide for 24 h. Positive % is indicated in each panel;
(b) Quantificative analysis of DAPI-positive population. Data are presented as mean ± S.D. (n = 3). Asterisks indicate statistically significant differences
compared to control (P < 0.001).
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50 μM C2-ceramide for 24 h (Figure 2a). Apparently, the
G1 arrest activities in cells treated with C2-ceramide
showed a significant increase at higher concentration
(P < 0.001) (Figure 2b).Figure 5 p-Akt and p-NFκB levels of C2-ceramide-treated H1299 lung
of C2-ceramide for 24 h. After treatment, the protein lysates were resolved
with specific antibodies and detected signals using an enhanced chemilum
(b) The changes of protein level of survivin, cyclin A2 and Bax. β-actin as aApoptosis induction of C2-Ceramide-treated H1299 lung
cancer cells
In Figure 2a, the profiles of PI/annexin V-positive percent-
ages were shown for the treatments with vehicle control or
0, 10, 20, and 50 μM of C2-ceramide for 24 h. After 24 hcancer cells. Cells treated with different concentrations (0 to 50 μM)
by SDS-PAGE, transferred onto nitrocellulose membranes and probed
inescence kit. (a) The changes of Akt and NFκB phosphorylation.
n internal control.
Figure 6 Schematic diagram of hypothesized mechanism of
C2-ceramide-induced apoptosis of lung cancer cells. C2-ceramide
inhibits the activity of both Akt and NF-κB, causing the down-regulation
of pro-survival survivin and cell cycle promoter cyclin A2. On the
contrary, C2-ceramide increases the protein level of pro-apoptotic
Bax. As a result, C2-creamide treatment causes cell cycle G1 arrest
and chromatin condensation, subsequently, triggering the apoptosis of
lung cancer cells.
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of H1299 lung cancer cells were significantly increased in a
dose–response manner for most concentrations (P < 0.05)
(Figure 3).
Chromatin condensation of C2-Ceramide-treated H1299
lung cancer cells
Chromatin condensation is one of the most important
markers for apoptotic cells [29]. The apoptotic effect of
C2-ceramide-treated H1299 lung cancer cells was further
examined by the flow cytometry-based DAPI assay. The
profiles of DAPI-positive percentages of 0, 10, 20, and
50 μM C2-ceramide for 24 h were shown (Figure 4a).
The DAPI-positive percentages of C2-ceramide-treated
H1299 lung cancer cells were significantly reduced in a
dose–response manner (P < 0.001) (Figure 4b).
Modulation of p-Akt and p-NFκB in C2-Ceramide-treated
H1299 lung cancer cells
The role of C2-Ceramide-induced modulating the
levels of p-Akt and p-NFκB in H1299 lung cancer cells
was examined by Western blotting. Both p-Akt and
p-NFκB levels in C2-Ceramide-treated H1299 cells were
significantly reduced at the concentration of 20 and 50 μM
(Figure 5a). Likewise, the protein levels of pro-survival
survivin and the cell cycle promoter cyclin A2 were down-
regulated dramatically. On the contrary, the protein level
of pro-apoptotic Bax was increased significantly following
C2-Ceramide treatment) (Figure 5b).
Discussion
The modulations of ceramide as the strategy for many
kinds of cancer therapies have been reported [18-21]. For
example, acid ceramidase was regarded as the target for
breast cancer therapy [19] because it can hydrolyze cer-
amide, and thus reduce its intracellular levels. Previous
study showed that C2-ceramide is not very harmful to
normal cells. For example, the IC50 (24 h) of human
dermal neonatal fibroblast (HDNF) cells for C2−cer-
amide was 66.5 μM [30], suggesting the moderately se-
lective anti-proliferative effect of C2−ceramide toward
cancer cells. In the current study, we found that the
C2-ceramide induced apoptosis of H1299 lung cancer
cells. It provides the idea that pharmacological modula-
tion of sphingolipid metabolism can enrich the tumor
cell ceramide for cancer chemotherapy.
Sometimes the degree of the sub-G1 accumulation
may not appear in concert with the apoptosis in terms
of Annexin V/PI staining. For example, no sub-G1 accu-
mulation was found in C2-ceramide-treated H1299 lung
cancer cells at 24 h treatment, but it still showed the
apoptosis-inducible effects in terms of Annexin V/PI
and DAPI-based chromatin condensation assays using
flow cytometry. Similarly, (−)-Anonaine inhibits growthof H1299 cells without sub-G1 accumulation before 48 h
incubation, however, the (−)-Anonaine ends up increas-
ing apoptosis at 72 h treatment [31]. Therefore, the ab-
sence of sub-G1 accumulation in C2-ceramide-treated
H1299 at 24 h treatment may be due to the detection tim-
ing. Furthermore, chromatin condensation was thought to
be one of hallmarks in apoptotic cells [32,33]. However,
some study indicated that certain stresses such as heat
shock may induce a non-apoptotic chromosome conden-
sation [34]. For example, Plehn-Dujowich’s work found
the non-apoptotic chromatin condensation [34]. Accord-
ingly, in our study, the non-apoptosis inducing dose of
20 μM C2-ceramide caused stress-induced chromatin con-
densation, which may explain the reason that C2-ceramide
induces anti-proliferation without apoptosis (Figure 4).
Eventually, a higher dose of 50 μM C2-ceramide causes
the apoptotic chromatin condensation, resulting in cell
death of H1299 cells.
Previously, C2-ceramide-induced H1299 cells was in-
vestigated [22,23]. Demarchi’s work indicated that C2-
ceramide triggers the NFκB-dependent survival pathway.
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decreases the level of phosphorylated NFκB (Figure 5a).
This may due to the different duration of NFκB treatment
(8 h vs. 24 h for Demarchi and Lin respectively). Import-
antly, our study demonstrated that C2-ceramide potently
inhibits Akt phosphorylation of H1299 cells at the of 20
and 50 μM, suggesting that it will be an advantage of treat-
ing lung cancer with constitutively phosphorylated Akt.
C2-ceramide also causes the down-regulation of survivin
and cyclin A2 (Figure 5b), and the up-regulation of pro-
apoptotic factor Bax in H1299 cells. This may sensitize
lung cancer cells towards proliferation inhibition and
apoptosis (Figure 6). The results of this study demon-
strated that that C2-ceramide treatment exerts anti-
growth potential against human non-small cell lung can-
cer cells H1299 in a dose-responsive manner. C2-ceramide
also reduces the pro-survival proteins Akt and NFκB,
causing the down-regulation of survivin and cyclin A2,
which are reported to frequently overexpress in non-small
cell lung cancer [35]. This may sensitize lung cancer cells
towards proliferation inhibition and apoptosis (Figure 6).
Accordingly, the above results suggested that C2-ceramide
may be a promising reagent for lung cancer treatment or
adjuvant therapy in future.
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